The partnership aims to co-develop full-stack AI infrastructure, targeting enterprise and industrial use cases in Japan and beyond.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
A notorious ransomware group claims to have stolen sensitive corporate data, putting Oracle's reputation and customer security under scrutiny.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.